

Pascal Benkert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/729982/publications.pdf>

Version: 2024-02-01

61
papers

8,018
citations

218677

26
h-index

123424

61
g-index

62
all docs

62
docs citations

62
times ranked

13313
citing authors

#	ARTICLE	IF	CITATIONS
1	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2022, 28, 71-81.	3.0	10
2	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2022, 28, 573-582.	3.0	17
3	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	32
4	Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia. <i>Annals of Neurology</i> , 2022, 91, 676-681.	5.3	8
5	Development of an age-adjusted model for blood neurofilament light chain. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 444-453.	3.7	19
6	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
7	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. <i>Annals of Neurology</i> , 2022, 91, 814-820.	5.3	7
8	Monitoring strategies for clinical intervention studies. <i>The Cochrane Library</i> , 2022, 2022, MR000051.	2.8	5
9	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. <i>Frontiers in Neuroscience</i> , 2022, 16, 819010.	2.8	15
10	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	9.0	41
11	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	3.0	14
12	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. <i>Multiple Sclerosis Journal</i> , 2021, 27, 439-448.	3.0	8
13	Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 941-949.	3.6	16
14	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2021, 89, 610-616.	5.3	68
15	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	2.0	8
16	Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. <i>Critical Care</i> , 2021, 25, 32.	5.8	16
17	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the MEMO study. <i>BMC Medicine</i> , 2021, 19, 38.	5.5	24
18	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 512-519.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.2	44
20	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 477-489.	5.3	16
21	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e543-e553.	1.1	54
22	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, e1466-e1474.	1.1	20
23	Increased Serum Neurofilament Light and Thin Ganglion Cell Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	29
24	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	3.0	9
25	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 17.	1.8	4
26	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, 3, e000192.	1.6	1
27	Factors influencing serum neurofilament light chain levels in normal aging. <i>Aging</i> , 2021, 13, 25729-25738.	3.1	38
28	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies. <i>Frontiers in Neuroscience</i> , 2021, 15, 791670.	2.8	2
29	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	43
30	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.1	61
31	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	3.7	35
32	Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. <i>European Journal of Neurology</i> , 2020, 27, 1066-1075.	3.3	21
33	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020, 94, e1201-e1212.	1.1	88
34	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	24
35	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. <i>Nature Communications</i> , 2020, 11, 812.	12.8	316
36	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. <i>Brain Communications</i> , 2020, 2, fcaa166.	3.3	24

#	ARTICLE	IF	CITATIONS
37	Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study. <i>Swiss Medical Weekly</i> , 2020, 150, w20318.	1.6	13
38	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	9.0	129
39	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 989-999.	2.8	148
40	Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?. <i>Clinical Infectious Diseases</i> , 2019, 70, 653-659.	5.8	13
41	Monitoring strategies for clinical intervention studies. <i>The Cochrane Library</i> , 2019, , .	2.8	1
42	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 777-785.	3.0	46
43	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018, 83, 1162-1173.	5.3	98
44	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 2382-2391.	7.6	345
45	Generating evidence on a risk-based monitoring approach in the academic setting â€“ lessons learned. <i>BMC Medical Research Methodology</i> , 2017, 17, 26.	3.1	14
46	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	5.3	768
47	Validity of mobile electronic data capture in clinical studies: a pilot study in a pediatric population. <i>BMC Medical Research Methodology</i> , 2017, 17, 163.	3.1	11
48	Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a personâ€“centred approach. <i>Journal of Viral Hepatitis</i> , 2016, 23, 697-707.	2.0	3
49	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. <i>PLoS ONE</i> , 2016, 11, e0152347.	2.5	38
50	Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 4994.	3.3	24
51	Heart Failure Therapyâ€“Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. <i>Journal of Cardiac Failure</i> , 2013, 19, 821-828.	1.7	69
52	Comparison of ⁶⁸ Ga-DOTANOC and ⁶⁸ Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2013, 54, 364-372.	5.0	184
53	Diagnosis and treatment of iron deficiency in medical inpatients at a Swiss tertiary university referral hospital: a retrospective observational cohort study of clinical practice. <i>Swiss Medical Weekly</i> , 2013, 143, w13847.	1.6	4
54	Improving your target-template alignment with MODalign. <i>Bioinformatics</i> , 2012, 28, 1038-1039.	4.1	10

#	ARTICLE	IF	CITATIONS
55	Toward the estimation of the absolute quality of individual protein structure models. <i>Bioinformatics</i> , 2011, 27, 343-350.	4.1	1,855
56	Global and local model quality estimation at CASP8 using the scoring functions QMEAN and QMEANclust. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 77, 173-180.	2.6	56
57	QMEANclust: estimation of protein model quality by combining a composite scoring function with structural density information. <i>BMC Structural Biology</i> , 2009, 9, 35.	2.3	131
58	Protein structure homology modeling using SWISS-MODEL workspace. <i>Nature Protocols</i> , 2009, 4, 1-13.	12.0	1,092
59	QMEAN server for protein model quality estimation. <i>Nucleic Acids Research</i> , 2009, 37, W510-W514.	14.5	716
60	QMEAN: A comprehensive scoring function for model quality assessment. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 71, 261-277.	2.6	888
61	Refinement of unbound protein docking studies using biological knowledge. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 61, 1059-1067.	2.6	8